What the Study Found (In Plain English)
Published in Journal of affective disorders (2025), this phase iii randomized trial evaluating 354 human participants investigated: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). Key clinical takeaway: CT-152 resulted in depression symptom improvement and a favorable safety profile. Based on these data, CT-152 became the first FDA-authorized prescription DTx for the adjunctive treatment of MDD.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of affective disorders, 2025-11-01; N = 354; Rigor 87/100): CT-152 resulted in depression symptom improvement and a favorable safety profile. Based on these data, CT-152 became the first FDA-authorized prescription DTx for the adjunctive treatment of MDD.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.